Nami Mori

1.2k total citations
31 papers, 449 citations indexed

About

Nami Mori is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Nami Mori has authored 31 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hepatology, 20 papers in Epidemiology and 5 papers in Infectious Diseases. Recurrent topics in Nami Mori's work include Hepatitis C virus research (17 papers), Liver Disease Diagnosis and Treatment (13 papers) and Hepatitis B Virus Studies (13 papers). Nami Mori is often cited by papers focused on Hepatitis C virus research (17 papers), Liver Disease Diagnosis and Treatment (13 papers) and Hepatitis B Virus Studies (13 papers). Nami Mori collaborates with scholars based in Japan, Switzerland and Greece. Nami Mori's co-authors include Kazuaki Chayama, Michio Imamura, Shoichi Takahashi, Shintaro Takaki, Hidenori Ochi, Masataka Tsuge, Yoshifumi Fujimoto, T Maekawa, Hiromi Abe and Nobuhiko Hiraga and has published in prestigious journals such as Hepatology, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Nami Mori

29 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nami Mori Japan 12 324 319 64 41 27 31 449
Theodoros Christophides Cyprus 5 308 1.0× 190 0.6× 56 0.9× 68 1.7× 67 2.5× 12 701
Jacek Juszczyk Poland 12 334 1.0× 332 1.0× 66 1.0× 19 0.5× 61 2.3× 54 495
James R. Burton United States 9 304 0.9× 441 1.4× 125 2.0× 43 1.0× 27 1.0× 11 564
Guiqiang Wang China 10 405 1.3× 335 1.1× 38 0.6× 23 0.6× 49 1.8× 17 490
Zhiliang Gao China 13 311 1.0× 303 0.9× 66 1.0× 31 0.8× 104 3.9× 59 520
Yunjian Sheng China 12 187 0.6× 141 0.4× 56 0.9× 23 0.6× 61 2.3× 34 327
Lingyao Du China 12 314 1.0× 286 0.9× 51 0.8× 41 1.0× 119 4.4× 60 489
Honglian Gui China 13 340 1.0× 306 1.0× 51 0.8× 15 0.4× 55 2.0× 27 494
Minoru Ayada Japan 12 170 0.5× 268 0.8× 81 1.3× 25 0.6× 21 0.8× 22 432
Marzia Margotti Italy 10 317 1.0× 323 1.0× 80 1.3× 17 0.4× 34 1.3× 19 449

Countries citing papers authored by Nami Mori

Since Specialization
Citations

This map shows the geographic impact of Nami Mori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nami Mori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nami Mori more than expected).

Fields of papers citing papers by Nami Mori

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nami Mori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nami Mori. The network helps show where Nami Mori may publish in the future.

Co-authorship network of co-authors of Nami Mori

This figure shows the co-authorship network connecting the top 25 collaborators of Nami Mori. A scholar is included among the top collaborators of Nami Mori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nami Mori. Nami Mori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Komiyama, Yasuyuki, Nobuharu Tamaki, Keiji Tsuji, et al.. (2025). Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study. JGH Open. 9(9). e70277–e70277. 1 indexed citations
2.
Tsuji, Keiji, Nobuharu Tamaki, Nami Mori, et al.. (2025). Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group. Hepatology Research. 55(5). 675–684. 2 indexed citations
3.
Takaki, Shintaro, Michio Imamura, Shuji Yamaguchi, et al.. (2020). Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. Clinical Journal of Gastroenterology. 13(6). 1233–1238. 3 indexed citations
4.
Okanobu, Hideharu, Ritsuo Mouri, Yumiko Yamashita, et al.. (2020). Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study. Esophagus. 18(3). 669–675. 14 indexed citations
5.
Mori, Nami, Takayuki Fukuhara, Shintaro Takaki, et al.. (2019). Regression of Idiopathic Thrombocytopenic Purpura in a Patient With Eradication of Hepatitis C Virus by Direct‐Acting Antivirals. Hepatology. 71(1). 389–391. 6 indexed citations
6.
Takaki, Shintaro, Takayuki Fukuhara, Nami Mori, & Keiji Tsuji. (2019). High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma. Molecular and Clinical Oncology. 12(1). 60–68. 6 indexed citations
7.
Goto, Kumiko, Keiji Tsuji, Yohji Honda, et al.. (2017). Familial Occurrence of a Congenital Portosystemic Shunt of the Portal Vein. Hiroshima University Acedemic Information Repository (Hiroshima University). 66(3). 85–90.
8.
Honda, Yohji, Shintaro Takaki, Nami Mori, et al.. (2017). Portosystemic Encephalopathy without Liver Disease Masquerading as Dementia.. PubMed. 66(1). 17–20. 1 indexed citations
9.
Inagaki, Katsuaki, Shintaro Takaki, Yohji Honda, et al.. (2017). A case of hepatitis E virus infection in a patient with primary biliary cholangitis. Kanzo. 58(3). 183–190. 6 indexed citations
10.
Morio, Reona, Michio Imamura, Yoshiiku Kawakami, et al.. (2016). Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. Journal of Gastroenterology. 52(4). 504–511. 11 indexed citations
11.
Mori, Nami, Michio Imamura, Shintaro Takaki, et al.. (2014). Hepatitis C Virus (HCV) Reactivation Caused by Steroid Therapy for Dermatomyositis. Internal Medicine. 53(23). 2689–2693. 10 indexed citations
12.
Mori, Nami, Fumitaka Suzuki, Yusuke Kawamura, et al.. (2012). Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. Journal of Gastroenterology. 47(9). 1022–1029. 22 indexed citations
13.
Tsuge, Masataka, Tsuyoshi Hatakeyama, Hiromi Abe, et al.. (2010). Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. Antiviral Therapy. 15(8). 1087–1097. 10 indexed citations
14.
15.
Noguchi, Chiemi, Michio Imamura, Masataka Tsuge, et al.. (2009). G‐to‐A Hypermutation in Hepatitis B Virus (HBV) and Clinical Course of Patients with Chronic HBV Infection. The Journal of Infectious Diseases. 199(11). 1599–1607. 20 indexed citations
16.
Uka, Kiminori, Hiroshi Aikata, Nami Mori, et al.. (2008). Combination Therapy of Oral Fluoropyrimidine Anticancer Drug S-1 and Interferon Alpha for HCC Patients with Extrahepatic Metastases. Oncology. 75(1-2). 8–16. 19 indexed citations
17.
Tsuge, Masataka, Chiemi Noguchi, Nobuhiko Hiraga, et al.. (2008). A case of fulminant hepatic failure caused by hepatitis E virus. Clinical Journal of Gastroenterology. 1(2). 69–74. 2 indexed citations
18.
Aikata, Hiroshi, Kiminori Uka, Shintaro Takaki, et al.. (2007). Efficacy of Percutaneous Cementoplasty for Bone Metastasis from Hepatocellular Carcinoma. Oncology. 72(5-6). 285–292. 19 indexed citations
19.
Yatsuji, Hiromi, Nobuhiko Hiraga, Nami Mori, et al.. (2007). Successful treatment of an entecavir‐resistant hepatitis B virus variant. Journal of Medical Virology. 79(12). 1811–1817. 29 indexed citations
20.
Hatakeyama, Tsuyoshi, Chiemi Noguchi, Nobuhiko Hiraga, et al.. (2007). Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine†. Hepatology. 45(5). 1179–1186. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Theodoros Christophides Breakdown of academic impact, for papers by Jacek Juszczyk Breakdown of academic impact, for papers by James R. Burton Breakdown of academic impact, for papers by Guiqiang Wang Breakdown of academic impact, for papers by Zhiliang Gao Breakdown of academic impact, for papers by Yunjian Sheng Breakdown of academic impact, for papers by Lingyao Du Breakdown of academic impact, for papers by Honglian Gui Breakdown of academic impact, for papers by Minoru Ayada Breakdown of academic impact, for papers by Marzia Margotti
Rankless by CCL
2026